Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
SEK 50.8
(-4.87%)
SEK 50.8
(-4.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -134.61 Million SEK | -104.56% |
| 2022 | -65.8 Million SEK | -47.62% |
| 2021 | -44.57 Million SEK | 38.02% |
| 2020 | -71.91 Million SEK | -52.37% |
| 2019 | -47.2 Million SEK | -19.75% |
| 2018 | -39.41 Million SEK | -9.06% |
| 2017 | -36.14 Million SEK | 5.12% |
| 2016 | -38.09 Million SEK | -84.77% |
| 2015 | -20.61 Million SEK | -212.73% |
| 2014 | -6.59 Million SEK | -2780.77% |
| 2013 | -228.82 Thousand SEK | -13321.0% |
| 2012 | -1705.00 SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -44.27 Million SEK | -48.6% |
| 2024 Q1 | -29.79 Million SEK | 45.86% |
| 2023 Q2 | -30.95 Million SEK | -27.4% |
| 2023 FY | -136.76 Million SEK | -107.83% |
| 2023 Q4 | -55.03 Million SEK | -63.23% |
| 2023 Q3 | -33.71 Million SEK | -8.94% |
| 2023 Q1 | -24.29 Million SEK | 40.39% |
| 2022 Q2 | 1.75 Million SEK | 109.22% |
| 2022 Q4 | -40.75 Million SEK | -426.17% |
| 2022 FY | -65.8 Million SEK | -47.62% |
| 2022 Q1 | -19.06 Million SEK | -18.46% |
| 2022 Q3 | -7.74 Million SEK | -540.61% |
| 2021 Q4 | -16.09 Million SEK | -7158.33% |
| 2021 FY | -44.57 Million SEK | 38.02% |
| 2021 Q1 | 452 Thousand SEK | 101.7% |
| 2021 Q3 | 228 Thousand SEK | 100.78% |
| 2021 Q2 | -29.16 Million SEK | -6552.21% |
| 2020 Q1 | 1.2 Million SEK | 104.4% |
| 2020 Q3 | -18.58 Million SEK | 33.42% |
| 2020 Q4 | -26.62 Million SEK | -43.25% |
| 2020 FY | -71.91 Million SEK | -52.37% |
| 2020 Q2 | -27.91 Million SEK | -2414.68% |
| 2019 Q4 | -27.42 Million SEK | -149.17% |
| 2019 Q3 | -11 Million SEK | -38.92% |
| 2019 Q2 | -7.92 Million SEK | -752.85% |
| 2019 FY | -47.2 Million SEK | -19.75% |
| 2019 Q1 | -929 Thousand SEK | 96.11% |
| 2018 Q3 | -7.68 Million SEK | -697.43% |
| 2018 Q1 | -9.14 Million SEK | -0.94% |
| 2018 FY | -39.41 Million SEK | -9.06% |
| 2018 Q4 | -23.87 Million SEK | -210.76% |
| 2018 Q2 | 1.28 Million SEK | 114.06% |
| 2017 Q2 | -13.82 Million SEK | -61.46% |
| 2017 Q1 | -8.56 Million SEK | 39.32% |
| 2017 FY | -36.14 Million SEK | 5.12% |
| 2017 Q3 | -4.57 Million SEK | 66.94% |
| 2017 Q4 | -9.05 Million SEK | -98.18% |
| 2016 Q4 | -14.11 Million SEK | -78.63% |
| 2016 Q2 | -10.97 Million SEK | -115.07% |
| 2016 Q1 | -5.1 Million SEK | 6.73% |
| 2016 FY | -38.09 Million SEK | -84.77% |
| 2016 Q3 | -7.9 Million SEK | 28.02% |
| 2015 Q3 | -5.47 Million SEK | -13.12% |
| 2015 Q1 | -4.83 Million SEK | 0.0% |
| 2015 FY | -20.61 Million SEK | -212.73% |
| 2015 Q4 | -5.47 Million SEK | 0.0% |
| 2015 Q2 | -4.83 Million SEK | 0.0% |
| 2014 FY | -6.59 Million SEK | -2780.77% |
| 2013 FY | -228.82 Thousand SEK | -13321.0% |
| 2012 FY | -1705.00 SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 45.933% |
| Ziccum AB (publ) | -21.56 Million SEK | -524.383% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -720.785% |
| BioArctic AB (publ) | 252.64 Million SEK | 153.284% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -15831.006% |
| Mendus AB (publ) | -100.65 Million SEK | -33.748% |
| Genovis AB (publ.) | 54.22 Million SEK | 348.261% |
| Intervacc AB (publ) | -93.57 Million SEK | -43.854% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -767.825% |
| Active Biotech AB (publ) | -46.48 Million SEK | -189.599% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 847.498% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -142.916% |
| Aptahem AB (publ) | -10.1 Million SEK | -1232.214% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 58.129% |
| Kancera AB (publ) | -65.04 Million SEK | -106.969% |
| Fluicell AB (publ) | -26.87 Million SEK | -400.826% |
| Saniona AB (publ) | -81.06 Million SEK | -66.061% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -988.166% |
| Biovica International AB (publ) | -126.07 Million SEK | -6.777% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -216.709% |
| AcouSort AB (publ) | -17.48 Million SEK | -669.812% |
| Xintela AB (publ) | -57.23 Million SEK | -135.188% |
| Abliva AB (publ) | -96.54 Million SEK | -39.43% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 58.554% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -3740.713% |
| OncoZenge AB (publ) | -15.9 Million SEK | -746.541% |
| Amniotics AB (publ) | -29.07 Million SEK | -363.031% |
| 2cureX AB (publ) | -36.36 Million SEK | -270.203% |
| CombiGene AB (publ) | -36.3 Million SEK | -270.793% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -819.515% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 64.98% |
| Camurus AB (publ) | 532.35 Million SEK | 125.287% |
| Corline Biomedical AB | -1.78 Million SEK | -7428.915% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 25.529% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -222.954% |
| I-Tech AB | 24.43 Million SEK | 650.919% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 82.927% |
| Cyxone AB (publ) | -21.66 Million SEK | -521.472% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -27.039% |
| Biosergen AB | -27.26 Million SEK | -393.736% |
| Cantargia AB (publ) | -290.01 Million SEK | 53.583% |
| NextCell Pharma AB | -43.17 Million SEK | -211.815% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 25.529% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -687.405% |
| Nanologica AB (publ) | -69.96 Million SEK | -92.412% |
| SynAct Pharma AB | -224.49 Million SEK | 40.036% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -204.729% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -461.975% |
| LIDDS AB (publ) | -40.67 Million SEK | -230.966% |
| Lipum AB (publ) | -37.25 Million SEK | -261.349% |
| BioInvent International AB (publ) | -369.94 Million SEK | 63.611% |
| Alzinova AB (publ) | -16.52 Million SEK | -714.774% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 46.886% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -2005.612% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -16.984% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -568.439% |
| Simris Alg AB (publ) | -36.63 Million SEK | -267.455% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 8.153% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 56.635% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -21.371% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -1063.903% |